Health Trials

Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past

1

Review clinical trials related to Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.

Participants needed: 252
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Runshi Pharmaceutical Technology Co., LtdUpdated: Sep 5, 2024
Eligibility criteria

1. Aged 18-75 (including) years old; 2. Gastric adenocarcinoma or gastroesophage...

Aged 18-75 (including) years old; [+17]

Read more